Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the sale, the insider now owns 42,246 shares in the company, valued at $1,901,070. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $142,228.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.

RxSight Stock Performance

RxSight stock traded down $0.32 during mid-day trading on Tuesday, reaching $46.06. The company’s stock had a trading volume of 229,941 shares, compared to its average volume of 488,755. RxSight, Inc. has a 12-month low of $28.88 and a 12-month high of $66.54. The company has a market capitalization of $1.86 billion, a P/E ratio of -55.49 and a beta of 1.19. The firm’s fifty day moving average price is $49.20 and its two-hundred day moving average price is $52.57.

Analyst Ratings Changes

Several equities analysts have recently commented on RXST shares. Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group started coverage on RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Stifel Nicolaus cut their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $61.63.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. M&G Plc lifted its stake in RxSight by 12.4% in the second quarter. M&G Plc now owns 159,005 shares of the company’s stock worth $9,540,000 after purchasing an additional 17,577 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of RxSight by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after acquiring an additional 40,500 shares during the last quarter. Algert Global LLC bought a new position in shares of RxSight during the second quarter valued at about $2,488,000. Bank of New York Mellon Corp increased its position in shares of RxSight by 17.0% during the second quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company’s stock valued at $7,190,000 after buying an additional 17,368 shares during the period. Finally, Baillie Gifford & Co. increased its position in shares of RxSight by 17.0% during the third quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after buying an additional 60,789 shares during the period. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.